Phenomix Sciences is a precision obesity medicine company focused on helping conquer obesity globally through the use of our proprietary AI models, tests, unique data sets, and advanced analytics.
We believe that the key to conquering obesity is unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease
Background
Mayo Clinic physicians, scientists, and researchers, Andres Acosta, M.D. Ph.D., and Michael Camilleri, M.D. D.Sc., founded the company in 2017 after 10 years of rigorous clinical research focused on uncovering the pathophysiology behind the variability in response to obesity treatments. They were able to breakdown the pathophysiology of obesity into four key underlying mechanisms, now called phenotypes:
This phenotype may present with an increased occurance of hunger signaling throughout the day due to genetic variations affecting post-prandial satiety pathways
Hungry Brain (satiation)
This phenotype may present with the ability to consume an increased volume of calories during a meal due to genetic variants affecting satiation pathways.
Emotional Hunger (hedonic eating)
This phenotype may present with an increased appetite and cravings in response to both positive and negative emotions due ot genetic variations affecting neurotransmittersignaling in the brain.
Slow Burn (energy expenditure)
This phenotype may present with an decreased lean mass leading to a reduced resting energy expenditure due to genetic variations affecting body mass composition and overall metabolic rate.
Phenomix Sciences Obesity Platform
Phenomix believes that the key to understanding obesity and reducing the variability in treatment response is our unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease.
Our Phenomix Sciences Obesity Platform (PSIOP™) is designed to integrate our capabilities in machine learning, AI modeling, and clinical development to produce novel insights that advance our understanding, and therefore ability to address obesity as a disease. The platform’s data intelligence is then leveraged to generate better accuracy in predicting individual patient response to specific weight loss interventions.
MyPhenome® Test - the FIRST genetic test for targeted obesity therapy guidance
In pursuit of our goal to manage obesity across all stages and phenotypes of the disease, in 2024 we launched the MyPhenome® test to obesity specialists and obesity clinics. MyPhenome® is now being offered in over 200 clinical practices nationwide.
We are proud and thankful for the support by our key strategic investors: the AMA’s innovation subsidiary -Health2047, Mayo Ventures, Labcorp Ventures, and DexCom Ventures.
